Advertisement
The roundtable discussion was the first of a series of calls to provideinvestors an opportunity to hear more about Vermillion's diagnostic programsand understand the various markets that the company seeks to address.Yesterday's forum served as a means to educate this audience about the currentstate of PAD and why there is a clinical need for a blood test that candetermine a person's risk of developing the disease. PAD, a serious conditionaffecting some eight to 12 million Americans, can double a person's risk ofheart attack and stroke, and increase the risk of amputation and death. Thereare treatments that can save the lives and limbs of these patients once thedisease is recognized.
Advertisement
"The signs and symptoms of PAD often go unnoticed, and as a result manypatients are not being properly diagnosed. We are in serious need of new,innovative tools to aid in the diagnosis and management of this life-threatening condition," said Dr. Cooke. "Together with Vermillion, we areworking to develop a simple blood test that will stratify an individual's riskof developing PAD. This will serve as an important advancement in the overallmanagement of the disease - benefiting both the patient and the physicianalike."
"Improving diagnosis of PAD, expediting treatment and enhancing patientoutcomes is a key goal for Vermillion, as well as for Dr. Cooke and hisresearch team at Stanford," said Gail Page, President and CEO of Vermillion."We believe that our PAD diagnostic program will achieve these goals, and lookforward to reporting additional clinical and commercial results in the comingmonths."
To access the archived Web cast of the conference call, visit the InvestorRelations section of Vermillion's Web site at http://www.vermillion.com.Additionally, a telephone replay of the roundtable discussion is availablethrough May 30, and may be accessed by dialing (800) 633-8284 from the UnitedStates and Canada or (+1 402) 977-9140 internationally. The replay pass codeis 21381902.
About Vermillion's PAD Diagnostic Test Program
In collaboration with Dr. Cooke and his research team at StanfordUniversity, Vermillion has developed a novel panel of biomarkers in an effortto determine the risk of PAD through a simple blood test. The company has anexclusive license agreement with Stanford to develop and commercialize thispanel.
About Vermillion
Vermillion, Inc. is dedicated to the discovery, development andcommercialization of novel high-value diagnostic tests that help physiciansdiagnose, treat and improve outcomes for patients. Vermillion, along with itsprestigious scientific collaborators, has diagnostic programs in oncology,hematology, cardiology and women's health. Vermillion is based in Fremont,California. Additional information about Vermillion can be found on the Web athttp://www.vermillion.com .
Forward Looking Statements This news release contains forward-lookingstatements that involve significant risks and uncertainties, includingstatements regarding Vermillion's plans, objectives, expectations andintentions. These forward-looking statements are based on Vermillion's currentexpectations. The Private Securities Litigation Reform Act of 1995 provides a"safe harbor" for such forward-looking statements. In order to comply with theterms of the safe harbor, Vermillion notes that a variety of factors couldcause actual results and experience to diffe
